Dennis Schmidt Pedersen has been appointed Senior Vice President Human Resources at Swedish Orphan Biovitrum AB (publ) (Sobi). Schmidt Pedersen joins Sobi from global pharmaceutical company Takeda where he has held the position as Director Human Resources, Northern Europe.
Schmidt Pedersen has a strong track record of leading positions in several international companies including Genzyme, Ferring Pharmaceuticals and A.P. Møller-Mærsk. He brings expertise in the transformation of local HR models to more integrated international operating models; developing and implementing regional and international HR processes, guidelines and policies; and cementing the role of people and talent management as an integrated part of the business internationally. "We are delighted to welcome Dennis to Sobi", said Geoffrey McDonough, President and CEO. "Dennis will help us to build the capacity and reach of our increasingly international organization, and to support the expansion of the cross-functional teams needed to address the opportunities in our current business and pipeline." Schmidt Pedersen will join Sobi in October, 2013. --- About Sobi Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within haemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com. For more information - not for publication Media relations Investor relations Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of Investor Communications Relations T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 [email protected] [email protected]
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.